Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025

Rhea-AI Summary

Lisata Therapeutics (Nasdaq: LSTA) will report third quarter 2025 financial results for the period ended September 30, 2025 on Thursday, November 6, 2025 after market close.

The company will host a conference call at 4:30 p.m. Eastern time the same day. Participants are encouraged to dial in 10 minutes early. Dial-in numbers: toll-free (800) 715-9871, toll/intl (646) 307-1963 with Conference ID 6375221. A live webcast will be available under the Investors & News section of Lisata’s website, with a replay posted two hours after the call and accessible for 12 months.

BASKING RIDGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the third quarter ended September 30, 2025, on Thursday, November 6, 2025, after the close of trading and will host a conference call at 4:30 p.m. Eastern time. To join the live conference call, please refer to the dial-in information provided below.

Conference Call Dial-in information:
Participant Toll-Free dial: (800) 715-9871
Participant Toll/Int'l dial: (646) 307-1963
Conference ID: 6375221

To avoid delays, we encourage participants to dial into the conference call 10 minutes ahead of the scheduled start time.

A live webcast of the call will also be accessible under the Investors & News section of Lisata’s website and will be available for replay beginning two hours after the conclusion of the call for 12 months.

About Lisata Therapeutics

Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform^® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into the first quarter of 2027, encompassing anticipated data milestones from its ongoing clinical trials. For a comprehensive overview of certepetide's mechanism of action, please view our informative short film. For more information on the Company, please visit www.lisata.com.

Contact:

Investors:
Lisata Therapeutics
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com

This press release was published by a CLEAR® Verified individual.

FAQ

When will Lisata Therapeutics (LSTA) release Q3 2025 results?

Lisata will release third quarter 2025 results on Thursday, November 6, 2025 after market close.

What time is Lisata Therapeutics (LSTA) Q3 2025 conference call and how do I join?

The conference call is at 4:30 p.m. ET on November 6, 2025; dial toll-free (800) 715-9871 or (646) 307-1963 using Conference ID 6375221.

Where can I access the Lisata (LSTA) earnings webcast and replay?

Access the live webcast from Lisata’s Investors & News webpage; a replay will be available two hours after the call and remain for 12 months.

Will Lisata (LSTA) provide a replay of the November 6, 2025 call and for how long?

Yes. A replay will be posted about two hours after the call and will be available for 12 months.

Is there a recommended time to join Lisata (LSTA) conference call to avoid delays?

Yes. Participants are encouraged to dial in 10 minutes before the scheduled 4:30 p.m. ET start to avoid delays.